Literature DB >> 12748215

Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.

E Bollano1, M Scharin Täng, A Hjalmarson, F Waagstein, B Andersson.   

Abstract

OBJECTIVE: To determine whether patients with congestive heart failure on different beta adrenoreceptor blocking drugs have similar haemodynamic responses to dobutamine.
DESIGN: Single centre, single blind, randomised, two period crossover study comparing carvedilol with metoprolol CR/XL. PATIENTS: Ten patients with stable chronic congestive heart failure (ejection fraction < 40%) on chronic treatment with metoprolol CR/XL.
METHODS: Patients were treated with carvedilol or metoprolol CR/XL (target dose 50 mg twice daily and 200 mg once daily, respectively) for eight weeks. Stress echocardiography was undertaken at the end of each maintenance period, using dobutamine 5 and 15 microg/kg/min.
RESULTS: No significant haemodynamic differences were seen at rest on the two treatments. There was a more pronounced increase in heart rate and cardiac output during dobutamine infusion when the patients were on metoprolol than when they were on carvedilol. Mean arterial pressure increased significantly when the patients were on carvedilol, and cardiac output increased during low dose dobutamine, without further change during high dose dobutamine. During the dobutamine infusion, there was no significant difference in ejection fraction between carvedilol and metoprolol treatment.
CONCLUSIONS: Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect. These findings may be clinically relevant when choosing an inotropic drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748215      PMCID: PMC1767680          DOI: 10.1136/heart.89.6.621

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography.

Authors:  N B Schiller
Journal:  Circulation       Date:  1991-09       Impact factor: 29.690

Review 2.  Carvedilol.

Authors:  W H Frishman
Journal:  N Engl J Med       Date:  1998-12-10       Impact factor: 91.245

3.  Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs.

Authors:  S F Vatner; R J McRitchie; E Braunwald
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

4.  Altered hemodynamic response to dobutamine in relation to the degree of preoperative beta-adrenoceptor blockade.

Authors:  J Tarnow; K Komar
Journal:  Anesthesiology       Date:  1988-06       Impact factor: 7.892

5.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

Review 6.  The pharmacology of dobutamine.

Authors:  R R Ruffolo
Journal:  Am J Med Sci       Date:  1987-10       Impact factor: 2.378

7.  Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.

Authors:  C Maack; T Elter; G Nickenig; K LaRosee; M Crivaro; A Stäblein; H Wuttke; M Böhm
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

8.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.

Authors:  E M Gilbert; W T Abraham; S Olsen; B Hattler; M White; P Mealy; P Larrabee; M R Bristow
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

9.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  9 in total

1.  Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery.

Authors:  Domenico Vitale; Vincenzo De Santis; Fabio Guarracino; Andrea Fontana; Fabio Pellegrini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2010-09-07       Impact factor: 5.460

Review 2.  Beta-blocker use in decompensated heart failure.

Authors:  Rami Alharethi; Ray E Hershberger
Journal:  Curr Heart Fail Rep       Date:  2006-06

3.  Positive inotropes in heart failure: a review article.

Authors:  Ahmad Amin; Majid Maleki
Journal:  Heart Asia       Date:  2012-01-01

4.  Beta-blocker therapy in unstable severe heart failure, evidence or experience?

Authors:  C L Meuwese; J H Kirkels; N de Jonge; H M Nathoe; P A Doevendans; C Klöpping
Journal:  Neth Heart J       Date:  2013-01       Impact factor: 2.380

Review 5.  Ivabradine: potential clinical applications in critically ill patients.

Authors:  Vincenzo De Santis; Domenico Vitale; Anna Santoro; Aurora Magliocca; Andrea Giuseppe Porto; Cecilia Nencini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2012-10-14       Impact factor: 5.460

6.  Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.

Authors:  Claes-Håkan Bergh; Bert Andersson; Ulf Dahlström; Kolbjorn Forfang; Matti Kivikko; Toni Sarapohja; Bengt Ullman; Gerhard Wikström
Journal:  Eur J Heart Fail       Date:  2010-04       Impact factor: 15.534

Review 7.  Current treatment options for early management in acute decompensated heart failure.

Authors:  Jonathan G Howlett
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

8.  β1-Adrenergic receptor signaling activates the epithelial calcium channel, transient receptor potential vanilloid type 5 (TRPV5), via the protein kinase A pathway.

Authors:  Eline A E van der Hagen; Kukiat Tudpor; Sjoerd Verkaart; Marla Lavrijsen; Annemiete van der Kemp; Femke van Zeeland; René J M Bindels; Joost G J Hoenderop
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

Review 9.  Acute decompensated heart failure update.

Authors:  John R Teerlink; Khalid Alburikan; Marco Metra; Jo E Rodgers
Journal:  Curr Cardiol Rev       Date:  2015
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.